[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2026; 10: (2) ; 10.12208/j.ijcr.20260071 .

Clinical intervention effects of EpiCor postbiotic on influenza-like illness and respiratory allergies in infants and children
EpiCor后生元在婴幼儿及儿童流感样病症与呼吸道过敏中的临床干预作用研究

作者： 邓莉 *

首都儿科研究所附属儿童医院感染科 北京

*通讯作者： 邓莉,单位：首都儿科研究所附属儿童医院感染科 北京；

引用本文: 邓莉 EpiCor后生元在婴幼儿及儿童流感样病症与呼吸道过敏中的临床干预作用研究[J]. 国际临床研究杂志, 2026; 10: (2) : 52-55.
Published: 2026/2/9 9:35:45

摘要

目的 探讨研究EpiCor后生元在婴幼儿及儿童流感样病症与呼吸道过敏中的临床干预作用。方法 本研究纳入2025年6月至2025年10月期间，年龄6月龄至14岁、接受流感样病症应急治疗、季节性预防或呼吸道过敏症状控制的儿童共101例，随机分为干预组（n=60）和对照组（n=41）。干预组：流感样病症应急治疗25例、流感样病症季节性预防17例、呼吸道过敏症状控制18例（均接受EpiCor后生元治疗）。对照组：流感样病症应急治疗21例、流感样病症季节性预防10例、呼吸道过敏症状控制10例（均接受安慰剂治疗）。分别比较两组在流感样病症应急治疗、季节性预防及呼吸道过敏症状控制方面的效果，主要观察指标包括症状发生率、持续时间、评分改善情况以及不良反应发生率。结果 干预组在应急治疗、季节性预防及呼吸道过敏症状控制方面的效果均优于对照组；两组不良反应发生率无显著差异。结论 在本研究观察条件下，EpiCor后生元对婴幼儿及儿童流感样病症的应急治疗、季节性预防及呼吸道过敏症状控制显示出积极效果，干预组相关指标较对照组改善，未见明显安全性差异，且总体安全性良好。

关键词： EpiCor后生元；婴幼儿；儿童；流感样病症；呼吸道过敏；临床干预效果

Abstract

Objective To investigate the clinical intervention effects of EpiCor postbiotic on influenza-like illness and respiratory allergies in infants and children.
Methods A total of 101 children aged 6 months to 14 years, who received emergency treatment for influenza-like illness, seasonal preventive treatment, or control of respiratory allergy symptoms between June and October 2025, were enrolled and randomly assigned to an intervention group (n=60) or a control group (n=41). The intervention group received EpiCor postbiotic, while the control group received a placebo. The outcomes, including symptom duration, symptom scores, and improvement of respiratory allergy symptoms, were compared between the two groups, along with the incidence of adverse reactions.
Results The intervention group showed superior outcomes in emergency treatment, seasonal prevention, and respiratory allergy symptom control compared to the control group. There was no significant difference in the incidence of adverse reactions between the two groups.
Conclusion   Under the conditions of this study, EpiCor postbiotic demonstrated positive effects in the emergency treatment and seasonal prevention of influenza-like illness, as well as in the control of respiratory allergy symptoms in infants and children. The intervention was associated with improvement in relevant indicators and showed a favorable overall safety profile.

Key words： EpiCor postbiotic; Infants; Children; Influenza-like illness; Respiratory allergies; Clinical intervention effect

参考文献 References

[1] 潘锋(整理).公众版儿童流感诊疗及预防指南发布[J].妇儿健康导刊,2024,3(23):8-9

[2] 薛帅帅,刘鹏,顾明珂,甘乾福.酵母后生元对畜禽动物肠道健康的影响机制[J].江西农业,2025(15):106-109

[3] 凌健棉,王盼,黎金彩,蔡赐美,周海泳,晏琦,胡文锋,李雪玲.后生元抗病毒性肠胃炎实验研究进展[J].微生物学通报,2025,52(1):46-59

[4] Moyad MA, Robinson LE, Kittelsrud JM, Reeves SG, Weaver SE, Guzman AI, Bubak ME. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2009 Aug;26(8):795-804.

[5] Pinheiro I, Robinson L, Verhelst A, Marzorati M, Winkens B, den Abbeele PV, Possemiers S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial. BMC Complement Altern Med. 2017 Sep 4;17(1):441.

[6] Singh RG, Garcia-Campayo V, Green JB, Paton N, Saunders JD, Al-Wahsh H, Crowley DC, Lewis ED, Evans M, Moulin M. Efficacy of a yeast postbiotic on cold/flu symptoms in healthy children: A randomized-controlled trial. Pediatr Res. 2024 Dec;96(7):1739-1748.